![]() |
![]() |
My Amedeo
![]() ![]() ![]() |
![]() |
|||||||||
Stroke prevention |
Prostate Cancer |
Free Subscription
1 AJR Am J Roentgenol |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Prostate Cancer is free of charge.
PI-RR: The Prostate Imaging for Recurrence Reporting System for MRI Assessment of
Local Prostate Cancer Recurrence After Radiation Therapy or Radical
Prostatectomy-A Review.
AJR Am J Roentgenol. 2023 Feb 1. doi: 10.2214/AJR.22.28665.
PubMed
Abstract available
Do not treat Bill Gates for prostate cancer! Algorithmic bias and causality in
medical prediction.
BJU Int. 2023 Jan 30. doi: 10.1111/bju.15951.
PubMed
Novel cuproptosis-related long non-coding RNA signature to predict prognosis in
prostate carcinoma.
BMC Cancer. 2023;23:105.
PubMed
Abstract available
Skull metastasis is a poor prognostic factor for prostate cancer patients with
bone metastasis: a retrospective study based on a Chinese population.
BMC Urol. 2023;23:13.
PubMed
Abstract available
A nomogram model for determining optimal patients for local therapy in metastatic
prostate cancer: a SEER database-based study.
BMC Urol. 2023;23:12.
PubMed
Abstract available
Transrectal versus transperineal prostate biopsy in detection of prostate cancer:
a retrospective study based on 452 patients.
BMC Urol. 2023;23:11.
PubMed
Abstract available
Beyond expression: role of phosphorylated residues of EZH2 in lineage plasticity
in prostate cancer.
Endocrinology. 2023 Jan 30:bqad023. doi: 10.1210.
PubMed
Abstract available
Re: Prostate Cancer Polygenic Risk Score and Prediction of Lethal Prostate
Cancer.
Eur Urol. 2023 Jan 27:S0302-2838(23)00013-1. doi: 10.1016/j.eururo.2023.
PubMed
Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to
Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial.
Eur Urol. 2023 Jan 27:S0302-2838(23)00056-8. doi: 10.1016/j.eururo.2023.
PubMed
Abstract available
Re: Percentage Gleason Pattern 4 and PI-RADS Score Predict Upgrading in Biopsy
Grade Group 2 Prostate Cancer Patients Without Cribriform Pattern.
Eur Urol. 2023 Jan 25:S0302-2838(23)00015-5. doi: 10.1016/j.eururo.2023.
PubMed
Re: Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic
Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission
Tomography.
Eur Urol. 2023;83:185-186.
PubMed
Relugolix: Five Reasons Why the US Food and Drug Administration Should Have
Exercised Restraint.
Eur Urol. 2023;83:101-102.
PubMed
Abstract available
Effect of Peritoneal Fixation (PerFix) on Lymphocele Formation in Robot-assisted
Radical Prostatectomy with Pelvic Lymphadenectomy: Results of a Randomized
Prospective Trial.
Eur Urol. 2023;83:154-162.
PubMed
Abstract available
Impact of hTERT peptide vaccine combined with androgen deprivation therapy and
radiotherapy in de novo metastatic prostate cancer: Long-term clinical
monitoring.
Int J Cancer. 2023 Jan 30. doi: 10.1002/ijc.34448.
PubMed
Abstract available
Dynamics of CXCR4 positive circulating tumor cells in prostate cancer patients
during radiotherapy.
Int J Cancer. 2023 Feb 2. doi: 10.1002/ijc.34457.
PubMed
Abstract available
VIM‑AS1 promotes proliferation and drives enzalutamide resistance in prostate
cancer via IGF2BP2‑mediated HMGCS1 mRNA stabilization.
Int J Oncol. 2023;62:34.
PubMed
Abstract available
WNT pathway mutations in metachronous oligometastatic castration-sensitive
prostate cancer.
Int J Radiat Oncol Biol Phys. 2023 Jan 25:S0360-3016(22)03628.
PubMed
Abstract available
Prediction of recovery time of urinary incontinence following robot-assisted
laparoscopic prostatectomy.
Int J Urol. 2023;30:77-82.
PubMed
Abstract available
T1 Mapping of the Prostate Using Single-Shot T1FLASH: A Clinical Feasibility
Study to Optimize Prostate Cancer Assessment.
Invest Radiol. 2022 Dec 8. doi: 10.1097/RLI.0000000000000945.
PubMed
Abstract available
An analysis of PSMA-PET/CT-positive lymph node distribution and their coverage by
different elective nodal radiation volumes in postoperative prostate cancer
patients.
J Nucl Med. 2023 Feb 2:jnumed.122.265159. doi: 10.2967/jnumed.122.265159.
PubMed
Abstract available
Model-constrained reconstruction accelerated with Fourier-based undersampling for
hyperpolarized [1-(13) C] pyruvate imaging.
Magn Reson Med. 2023;89:1481-1495.
PubMed
Abstract available
Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in
castration-resistant prostate cancer.
Oncogene. 2021;40:2625-2634.
PubMed
Abstract available
Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes
tumour growth.
Oncogene. 2023 Feb 1. doi: 10.1038/s41388-023-02604.
PubMed
Abstract available
[Corrigendum] Thymoquinone inhibits epithelial‑mesenchymal transition in prostate
cancer cells by negatively regulating the TGF‑beta/Smad2/3 signaling pathway.
Oncol Rep. 2023;49:54.
PubMed
Abstract available
Natural history of incidentally diagnosed prostate cancer after holmium laser
enucleation of the prostate.
PLoS One. 2023;18:e0278931.
PubMed
Abstract available
Narrative review of PET/CT performances at biochemical recurrence in prostate
cancer after radical prostatectomy and impact on patient disease management:
Revue narrative a propos des performances de la TEP/TDM en cas de recidive
biochimique apres pro
Prog Urol. 2022;32.
PubMed
Abstract available
Magnetic Resonance Imaging-Targeted Biopsy and Pretherapeutic Prostate Cancer
Risk Assessment: a Systematic Review: Biopsie ciblee par Imagerie par resonance
magnetique et evaluation pre-therapeutique du risque de cancer de la prostate :
revue systema
Prog Urol. 2022;32.
PubMed
Abstract available
The benefit of adopting Microultrasound in the prostate cancer imaging pathway: A
lesion-by-lesion analysis: Biopsies prostatiques guidee par micro-echographie,
quel benefice ? Une analyse lesion par lesion.
Prog Urol. 2022;32.
PubMed
Abstract available
How MRI is changing prostate cancer management: a focus on early detection and
active surveillance: Comment l'IRM est en train de revolutionner la prise en
charge du cancer de la prostate : focus sur la detection precoce et la
surveillance active.
Prog Urol. 2022;32.
PubMed
Abstract available
How imaging is changing prostate cancer management - Editorial: Comment
l'imagerie peut revolutionner le traitement du cancer de la prostate - Editorial.
Prog Urol. 2022;32.
PubMed
How PET-CT is Changing the Management of Non-metastatic Castration-resistant
Prostate Cancer?: Comment la TEP-TDM Peut Modifier la Prise en Charge du Cancer
de la Prostate Non Metastatique Resistant a la Castration ?
Prog Urol. 2022;32.
PubMed
Abstract available
Salvage stereotactic body radiation therapy for locally recurrent prostate cancer
following primary radiation therapy, are benefits worth toxicity risks?: A
systematic review.
Prostate. 2023 Jan 30. doi: 10.1002/pros.24491.
PubMed
Abstract available
The impact of genetic aberrations on response to radium-223 treatment for
castration-resistant prostate cancer with bone metastases.
Prostate. 2023 Jan 30. doi: 10.1002/pros.24489.
PubMed
Next-Generation Diffusion Imaging of Osseous Metastases.
Radiol Imaging Cancer. 2023;5:e220167.
PubMed
Diagnostic Performance and Clinical Impact of PSMA PET/CT versus mpMRI in
Patients with a High Suspicion of Prostate Cancer and Previously Negative Biopsy:
A Prospective Trial (PROSPET-BX).
Urol Int. 2023 Feb 1:1-7. doi: 10.1159/000528720.
PubMed
Abstract available
Thank you for your interest in scientific medicine.
This policy is made possible thanks to
a media sponsorship by